Cargando…

Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant genes

Paclitaxel (or Taxol(®)) is a first-line chemotherapeutic drug for the treatment of non-small cell lung cancer; however, resistance to the drug is an important factor, which influences the outcome of chemotherapy. The present study aimed to investigate the role of triptolide (TPL) in reversing Taxol...

Descripción completa

Detalles Bibliográficos
Autores principales: JIANG, NING, DONG, XIAO-PENG, ZHANG, SUO-LIN, YOU, QING-YONG, JIANG, XING-TAO, ZHAO, XIAO-GANG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686042/
https://www.ncbi.nlm.nih.gov/pubmed/26531258
http://dx.doi.org/10.3892/mmr.2015.4493
_version_ 1782406394212777984
author JIANG, NING
DONG, XIAO-PENG
ZHANG, SUO-LIN
YOU, QING-YONG
JIANG, XING-TAO
ZHAO, XIAO-GANG
author_facet JIANG, NING
DONG, XIAO-PENG
ZHANG, SUO-LIN
YOU, QING-YONG
JIANG, XING-TAO
ZHAO, XIAO-GANG
author_sort JIANG, NING
collection PubMed
description Paclitaxel (or Taxol(®)) is a first-line chemotherapeutic drug for the treatment of non-small cell lung cancer; however, resistance to the drug is an important factor, which influences the outcome of chemotherapy. The present study aimed to investigate the role of triptolide (TPL) in reversing Taxol-resistant human lung adenocarcinoma and to elucidate the underlying molecular mechanism of resistance reversal mediated by TPL. It was hypothesized that this experimental approach would assist in solving the problem of chemotherapeutic resistance in non-small cell lung cancer, thereby improving the clinical outcomes. The human Taxol-resistant lung adenocarcinoma cell line, A549/Taxol, was established. The resistance index of the cell line was calculated, according to the half maximal inhibitory concentration (IC(50)) of A549/Taxol IC(50) of A549, to be 51.87. The levels of apoptosis and the cell cycle in the A549/Taxol cell line were assessed to confirm the effects of TPL at three different concentrations (0.03, 0.3 and 3 µmol/l) and treatment durations (2, 4, 6 and 12 h) by flow cytometric analysis, and the inhibition of the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant proteins were determined by immunofluorescence and western blotting, respectively. The administration of TPL promoted cell apoptosis in the A549/Taxol lung adenocarcinoma Taxol-resistant cell line and also promoted cell cycle regulation. The drug was also able to elicit a reversal of the drug resistance. TPL inhibited the nuclear factor-κB (NF-κB) signaling pathway and the expression of NF-κB-regulated drug-resistant genes, including those for FLICE-like inhibitory protein, X-linked inhibitor of apoptosis protein, Bcl-2, Bcl-xL and cyclo-oxygenase-2. TPL exerted a marked drug-resistance-reversal effect on human lung adenocarcinoma Taxol resistance, and the effect was revealed to be dose- and time-dependent. In conclusion, TPL exerted its role in the process of resistance reversal by inhibiting the NF-κB signaling pathway, and the transcription and expression of NF-κB-regulated drug-resistant genes.
format Online
Article
Text
id pubmed-4686042
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-46860422015-12-31 Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant genes JIANG, NING DONG, XIAO-PENG ZHANG, SUO-LIN YOU, QING-YONG JIANG, XING-TAO ZHAO, XIAO-GANG Mol Med Rep Articles Paclitaxel (or Taxol(®)) is a first-line chemotherapeutic drug for the treatment of non-small cell lung cancer; however, resistance to the drug is an important factor, which influences the outcome of chemotherapy. The present study aimed to investigate the role of triptolide (TPL) in reversing Taxol-resistant human lung adenocarcinoma and to elucidate the underlying molecular mechanism of resistance reversal mediated by TPL. It was hypothesized that this experimental approach would assist in solving the problem of chemotherapeutic resistance in non-small cell lung cancer, thereby improving the clinical outcomes. The human Taxol-resistant lung adenocarcinoma cell line, A549/Taxol, was established. The resistance index of the cell line was calculated, according to the half maximal inhibitory concentration (IC(50)) of A549/Taxol IC(50) of A549, to be 51.87. The levels of apoptosis and the cell cycle in the A549/Taxol cell line were assessed to confirm the effects of TPL at three different concentrations (0.03, 0.3 and 3 µmol/l) and treatment durations (2, 4, 6 and 12 h) by flow cytometric analysis, and the inhibition of the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant proteins were determined by immunofluorescence and western blotting, respectively. The administration of TPL promoted cell apoptosis in the A549/Taxol lung adenocarcinoma Taxol-resistant cell line and also promoted cell cycle regulation. The drug was also able to elicit a reversal of the drug resistance. TPL inhibited the nuclear factor-κB (NF-κB) signaling pathway and the expression of NF-κB-regulated drug-resistant genes, including those for FLICE-like inhibitory protein, X-linked inhibitor of apoptosis protein, Bcl-2, Bcl-xL and cyclo-oxygenase-2. TPL exerted a marked drug-resistance-reversal effect on human lung adenocarcinoma Taxol resistance, and the effect was revealed to be dose- and time-dependent. In conclusion, TPL exerted its role in the process of resistance reversal by inhibiting the NF-κB signaling pathway, and the transcription and expression of NF-κB-regulated drug-resistant genes. D.A. Spandidos 2016-01 2015-11-02 /pmc/articles/PMC4686042/ /pubmed/26531258 http://dx.doi.org/10.3892/mmr.2015.4493 Text en Copyright: © Jiang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
JIANG, NING
DONG, XIAO-PENG
ZHANG, SUO-LIN
YOU, QING-YONG
JIANG, XING-TAO
ZHAO, XIAO-GANG
Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant genes
title Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant genes
title_full Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant genes
title_fullStr Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant genes
title_full_unstemmed Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant genes
title_short Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant genes
title_sort triptolide reverses the taxol resistance of lung adenocarcinoma by inhibiting the nf-κb signaling pathway and the expression of nf-κb-regulated drug-resistant genes
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686042/
https://www.ncbi.nlm.nih.gov/pubmed/26531258
http://dx.doi.org/10.3892/mmr.2015.4493
work_keys_str_mv AT jiangning triptolidereversesthetaxolresistanceoflungadenocarcinomabyinhibitingthenfkbsignalingpathwayandtheexpressionofnfkbregulateddrugresistantgenes
AT dongxiaopeng triptolidereversesthetaxolresistanceoflungadenocarcinomabyinhibitingthenfkbsignalingpathwayandtheexpressionofnfkbregulateddrugresistantgenes
AT zhangsuolin triptolidereversesthetaxolresistanceoflungadenocarcinomabyinhibitingthenfkbsignalingpathwayandtheexpressionofnfkbregulateddrugresistantgenes
AT youqingyong triptolidereversesthetaxolresistanceoflungadenocarcinomabyinhibitingthenfkbsignalingpathwayandtheexpressionofnfkbregulateddrugresistantgenes
AT jiangxingtao triptolidereversesthetaxolresistanceoflungadenocarcinomabyinhibitingthenfkbsignalingpathwayandtheexpressionofnfkbregulateddrugresistantgenes
AT zhaoxiaogang triptolidereversesthetaxolresistanceoflungadenocarcinomabyinhibitingthenfkbsignalingpathwayandtheexpressionofnfkbregulateddrugresistantgenes